Riskpilot← Back to searchSign inGet full accessDermans Medica Oy
OYDissolvedY-tunnus 2954310-5Näsilinnankatu 27-D26Medical specialists activities · NACE 8622Est. 2018— employees
Revenue 2024
EUR 303K
+10% vs 2023
EBITDA margin
191.3%
+19% vs 2023
Equity ratio
88.9%
Financial strength
Net profit 2024
EUR 113K
0% vs 2023
| Revenue | EUR 303K | +10% |
| EBITDA | EUR 580K | +19% |
| Net profit | EUR 113K | +0% |
| Total assets | EUR 529K | +28% |
| Equity | EUR 470K | +21% |
| Employees | — | — |
Legal name
Dermans Medica Oy
Y-tunnus number
2954310-5
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
23. marraskuuta 2018
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-11-30
Financial year
January – December
Company purpose
Erikoislääkäripalvelujen tuottaminen potilaille, alan koulutus- ja konsultointipalvelujen tuottaminen, luennointi sekä kustannustoiminta. Yhtiö voi omistaa, hallita ja vuokrata sekä välittää kiinteistöjä, liike- ja asuinhuoneistoja sekä kulkuneuvoja. Yhtiö voi harjoittaa arvopaperikauppaa.
Address
Näsilinnankatu 27-D26
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 199 | 204 | 219 | 275 | 303 |
| Staff expenses | −27 | −34 | −41 | 55 | 52 |
| EBITDA | 114 | 105 | 114 | 487 | 580 |
| Depreciation & amort. | — | — | — | — | 2 |
| EBIT | 114 | 105 | 114 | 141 | 146 |
| Net financials | 0 | 1 | 1 | 2 | −3 |
| Profit before tax | 114 | 106 | 115 | 142 | 143 |
| Tax | 23 | 21 | 23 | 28 | 30 |
| Net profit | 91 | 85 | 92 | 114 | 113 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 180 | 272 | 343 | 413 | 529 |
| Equity | 150 | 223 | 297 | 387 | 470 |
| Long-term debt | 1 | 41 | 44 | 15 | 17 |
| Short-term debt | 29 | 8 | 2 | 11 | 42 |
| Total debt | 30 | 49 | 46 | 25 | 59 |
EBITDA margin
191.3%
This company
15.8%
Market median
+1111% vs market
20202024
Equity ratio
88.9%
This company
38.2%
Market median
+133% vs market
20202024
Return on equity
24.2%
This company
18.4%
Market median
+32% vs market
20202024
Net profit margin
37.5%
This company
8.1%
Market median
+363% vs market
20202024
Asset turnover
0.57×
This company
1.12×
Market median
-49% vs market
20202024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-12-01 – 2021-11-30
- Annual report 2020Filed via PRH / YTJ · Period 2019-12-01 – 2020-11-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AV Deputy Member | Deputy Member | 2022 |
EK Chief Executive Officer | Chief Executive Officer | 2018 |
| Former (1) | ||
HP Deputy Member | Deputy Member | 2018 – 2022 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dermans Medica Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Akseli Viljami Mansikka | Deputy Member | 0 companies |
| Eriika Katariina Raikamo | Chief Executive Officer | 0 companies |
| Heikki Petteri Mansikka | Deputy Member | 0 companies |